Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Revenue of Akebia Therapeutics, Inc. (AKBA)
Revenue in 2023 (TTM): $194.62 M
According to Akebia Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $194.62 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Akebia Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $194.62 M | $120.47 M | $-6,868,000 | $-51,925,000 | $-51,925,000 |
| 2022 | $292.6 M | $207.81 M | $-43,259,000 | $-92,562,000 | $-106,009,000 |
| 2021 | $213.58 M | $60.18 M | $-225,960,000 | $-282,840,000 | $-244,870,000 |
| 2020 | $295.31 M | $-601,000 | $-340,996,000 | $-383,457,000 | $-349,867,000 |
| 2019 | $335 M | $189.67 M | $-247,642,000 | $-286,290,000 | $-279,659,000 |
| 2018 | $207.74 M | $200.06 M | $-178,094,000 | $-171,904,000 | $-171,904,000 |
| 2017 | $177.98 M | $177.37 M | $-76,057,000 | $-76,914,000 | $-76,914,000 |
| 2016 | $1.54 M | $-114,250,000 | $-136,164,000 | $-135,747,000 | $-135,747,000 |
| 2015 | $ | $-96,000 | $-61,417,000 | $-60,716,000 | $-60,716,000 |
| 2014 | $ | $-23,263,000 | $-37,891,000 | $-37,034,000 | $-37,034,000 |
| 2013 | $ | $ | $-12,462,333 | $-13,167,180 | $-13,167,180 |
| 2012 | $ | $ | $-6,551,299 | $-8,196,000 | $-8,196,000 |